years) as well as the rivaroxaban cohort was slightly younger (63.4 years) (Table 1). Comorbidities have been a lot more frequent mAChR1 Agonist MedChemExpress inside the warfarin cohort and significantly less frequent in the rivaroxaban cohort. The apixaban cohort had a greater prevalence of prior bleeding.Lund University, Malm Sweden; 2Kuopio University Hospital, Kuopio,5Finland; 3Evidera, Stockholm, Sweden; 4Evidera, London, United kingdom; Pfizer, Tadworth, United kingdom; Evidera, Waltham, Uk; 7University of Oslo, Oslo, Norway Background: Non-vitamin K oral anticoagulants (NOACs) are suggested as a first-line therapy for venous thromboembolism (VTE). Observational data from nationwide registries enable for the investigation of how clinical suggestions have impacted practice. Aims: The Venous Thromboembolism Treatment (VOLT) study describes the traits, remedy patterns, healthcare resource utilisation, comparative effectiveness, and security of OACs in treating VTE in Sweden, Finland, and Norway. This abstract presents the initial descriptive information from Sweden.ABSTRACT919 of|TABLE 1 Age and essential subgroups for patients with VTE in Sweden from 1 January 2013 to 30 September 2018 (general and for every single OAC cohort in the time of OAC remedy initiation). Abbreviations: DVT = deep vein thrombosis; PE = pulmonary embolism; SD = regular deviation; VTE = venous thromboembolism; = data suppressed to retain confidentiality, incorporates a cell with 5 sufferers.All Sufferers N = 33,Mean Age (SD) Form of VTE DVT ( ) PE (with or with no DVT) ( ) PE with DVT ( ) PE devoid of DVT ( ) Diagnostic Setting Inpatient overnight admission ( ) Outpatient take a look at or day admission ( ) Etiology Provoked Unprovoked ( ) 64.six (16.six) 17,952 (52.8 ) 16,027 (47.2 ) 1,481 (four.4 ) 14,546 (42.8 ) 15,965 (47.0 )Warfarin N = 11,65.9 (16.2) five,538 (49.1 ) five,741 (50.9 )Apixaban N = 9,64.six (16.7) four,662 (51.2 ) 4,439 (48.8 )Rivaroxaban N = 13,63.four (16.7) 7,563 (57.three ) five,626 (42.7 )Dabigatran N =62.9 (17.5) 172 (45.three ) 208 (54.7 )Edoxaban N =72.six (15.three) 17 (56.7 ) 13 (43.three )588 (five.two ) 5,153 (45.7 ) 6,294 (55.eight )361 (four.0 ) 4,078 (44.eight ) 4,011 (44.1 )515 (three.9 ) 5,111 (38.eight ) 5,438 (41.two )15 (three.9 ) 193 (50.eight ) 205 (53.9 ) 17 (56.7 )18,014 (53.0 )four,985 (44.two )5,090 (55.9 )7,751 (58.eight )175 (46.1 )13 (43.three )12,852 (37.8 ) 21,127 (62,2 )4,340 (38.five ) six,939 (61.5 )3,468 (38.1 ) 5,633 (61.9 )four,855 (36.eight ) 8,334 (63.2 )174 (45.eight ) 206 (54.two )15 (50.0 ) 15 (50.0 )PB1253|Neutralization from the Oral and Parenteral Anti-Xa Agents by Andexanet Alfa F. Siddiqui1; D. Hoppensteadt1; J. Walenga1; W. Jeske1; A. Tafur2; E. Ramacciotti1; J. FareedLoyola University Healthcare Center, Maywood, United states; 2NorthShore University Overall health Systems, Evanston, Usa Background: Beside the oral anti-Xa agents, parenteral types with the inhibitors of issue Xa for example otamixaban (Sanofi Aventis, Paris, France) and DX9065a (Mitsubishi Pharmaceuticals, Tokyo, Japan) have also been created. Andexanet alfa is often a broad-spectrum neuFIGURE 1 Proportion of oral anticoagulant prescription in Sweden for VTE treatment (2013018) Conclusions: From 2013 to 2018, there was a marked enhance in NOAC use for VTE therapy, specifically for rivaroxaban and apixaban, which coincides together with the publication of clinical suggestions recommending their use. tralizing agent for anti-Xa drugs. Aims: This study is created to compare the neutralization IL-2 Modulator list profile of andexanet alfa for apixaban and rivaroxaban with otamixaban and DX9065a in several laboratory assays.920 of|ABSTRACT
